Non pensavo questa notizia passasse così inosservata, ad ogni modo Giuseppe di Bella il Luglio scorsoè stato invitato al congresso Mondiale di Oncologia a presentare uno studio in merito alla famosa cura, studio che è stato accettato da una commissione costituita tra l'altro da 2 premi Nobel, di seguito posto un abstract
Ciò, unito ai centinaia di studi internazionali sulle sostanze della cdb, mi porta a pensare che la sperimentazione del98 fu fatta davvero in malafede,come testimonia tra l' altro la perizia dei nas sull'utilizzo di farmaci scaduti
Voi cosa pensatein merito?
(ABSTRACT ORIGINALE)
Title: Biological Oncotherapy According to The Di Bella Method (DBM), With The Synergic Use of Somatostatin and/or Octreotide, Bromocryptin and/or Cabergoline, Melatonin, Retinoids, Vitamins E, D3, and C, Chondroitin Sulfate, Calcium, and Minimal Apoptotic, Non Cytolytic Doses of Cyclophosphamide or Oncocarbide. Rationale of The DBM, and Results of 553 Cases of 29 Different Histotypes.
Dr. Giuseppe Di Bella
Via Marconi 51, Bologna, Italy
The aim of the Di Bella Method (DBM) is to try to overcome the high toxicity level and the limited efficacy of the current medical treatments for cancer, exploiting biological molecules currently undervalued in oncotherapy but which have a high degree of efficacy and a low level of toxicity and whose documented antitumoral effect is enhanced by reciprocal synergism. Survival is, nowadays, essentially due to surgery, reaching 29% at 5 years (Richards et al, BMJ. 2000 Apr 1;320(7239):895-8). Of this 29%, only 2.5% is due to chemotherapy (Morgan et al, 2004 Dec;16(8):549-60). This study is based on 14 years of observation, 225,000 patients, and 22 types of tumor. Half of the patients who survive for 5 years die in the long-term as a result of their tumor (Lopez et al, Gac Med Mex. 1998 Mar-Apr;134(2):145-51). The ASCO conference proceedings report that in solid tumors monoclonal antibodies increase survival by around two months, very rarely reaching or exceeding four months. The mechanism of action, the rationale and the results of the DBM are described, comparing them with those of chemotherapy and/or monoclonal antibodies in the same diseases and at the same disease stages. Using Melatonin, Retinoids, and vitamins E, D3, C, components of the extracellular matrix, the DBM reinforces those means that Physiology considers essential for life. Acting together, these differentiating molecules also have an antiangiogenic and antiproliferative effect. This effect is reinforced by Somatostatin and/or its analogs by negatively regulating highly mitogenic molecules such as GH and GH-dependent growth factors. Cabergoline and/or Bromocryptin, inhibitors of Prolactin, the ubiquitary mitogenic hormone, contribute to the antiproliferative and antiangiogenic synergism. The DBM foresees minimal apoptotic, non-cytotoxic and non-mutagenic doses of Cyclophosphamide or Oncocarbide, their tolerance being enhanced by Melatonin and by the vitamins included in the DBM. The preliminary results are reported of a retrospective observational study on 553 patients with 29 different histotypes, treated with the DBM. In all the tumors, albeit with important differences between them, the DBM achieved a clear improvement in the quality of life and a distinct improvement in survival, without any significant toxicity, for each type of tumor and stage with respect to the corresponding data in the literature regarding chemotherapy and/or monoclonal antibodies.